The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Crohn’s Disease Therapeutics-Global Market Insights and Sales Trends 2025
Synopsis
Prevalence of Crohn’s disease has increased in developing countries owing to industrialization, environmental factors such as differences in exposure to sunlight, changes in diet, smoking, and genetic characteristics. According to the Centers for Disease Control and Prevention (CDC), over 1 million Americans suffer from inflammatory bowel disease every year.
The global Crohn’s Disease Therapeutics market size is expected to reach US$ 3764.2 million by 2029, growing at a CAGR of 1.4% from 2023 to 2029. The market is mainly driven by the significant applications of Crohn’s Disease Therapeutics in various end use industries. The expanding demands from the Hospitals and Ambulatory Surgical Centers, are propelling Crohn’s Disease Therapeutics market. Non-Surgical, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Surgical segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Crohn’s Disease Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Crohn’s Disease Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Crohn’s Disease Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Crohn’s Disease Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Crohn’s Disease Therapeutics covered in this report include Johnson and Johnson Services Inc., Pfizer Inc., Allergan, AbbVie Inc., Takeda Pharmaceutical Company Limited, Celgene Corporation, Perrigo Company PLC, Ferring B.V. and Salix Pharmaceuticals, etc.
The global Crohn’s Disease Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Johnson and Johnson Services Inc.
Pfizer Inc.
Allergan
AbbVie Inc.
Takeda Pharmaceutical Company Limited
Celgene Corporation
Perrigo Company PLC
Ferring B.V.
Salix Pharmaceuticals
Gilead Sciences Inc.
Genentech Inc.
UCB India Private Limited.
Global Crohn’s Disease Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Crohn’s Disease Therapeutics market, Segment by Type:
Non-Surgical
Surgical
Global Crohn’s Disease Therapeutics market, by Application
Hospitals
Ambulatory Surgical Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Crohn’s Disease Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Prevalence of Crohn’s disease has increased in developing countries owing to industrialization, environmental factors such as differences in exposure to sunlight, changes in diet, smoking, and genetic characteristics. According to the Centers for Disease Control and Prevention (CDC), over 1 million Americans suffer from inflammatory bowel disease every year.
The global Crohn’s Disease Therapeutics market size is expected to reach US$ 3764.2 million by 2029, growing at a CAGR of 1.4% from 2023 to 2029. The market is mainly driven by the significant applications of Crohn’s Disease Therapeutics in various end use industries. The expanding demands from the Hospitals and Ambulatory Surgical Centers, are propelling Crohn’s Disease Therapeutics market. Non-Surgical, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Surgical segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Crohn’s Disease Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Crohn’s Disease Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Crohn’s Disease Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Crohn’s Disease Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Crohn’s Disease Therapeutics covered in this report include Johnson and Johnson Services Inc., Pfizer Inc., Allergan, AbbVie Inc., Takeda Pharmaceutical Company Limited, Celgene Corporation, Perrigo Company PLC, Ferring B.V. and Salix Pharmaceuticals, etc.
The global Crohn’s Disease Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Johnson and Johnson Services Inc.
Pfizer Inc.
Allergan
AbbVie Inc.
Takeda Pharmaceutical Company Limited
Celgene Corporation
Perrigo Company PLC
Ferring B.V.
Salix Pharmaceuticals
Gilead Sciences Inc.
Genentech Inc.
UCB India Private Limited.
Global Crohn’s Disease Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Crohn’s Disease Therapeutics market, Segment by Type:
Non-Surgical
Surgical
Global Crohn’s Disease Therapeutics market, by Application
Hospitals
Ambulatory Surgical Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Crohn’s Disease Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Crohn’s Disease Therapeutics
1.1 Crohn’s Disease Therapeutics Market Overview
1.1.1 Crohn’s Disease Therapeutics Product Scope
1.1.2 Crohn’s Disease Therapeutics Market Status and Outlook
1.2 Global Crohn’s Disease Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Crohn’s Disease Therapeutics Market Size by Region (2018-2029)
1.4 Global Crohn’s Disease Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Crohn’s Disease Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Crohn’s Disease Therapeutics Market Size (2018-2029)
1.6.1 North America Crohn’s Disease Therapeutics Market Size (2018-2029)
1.6.2 Europe Crohn’s Disease Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Crohn’s Disease Therapeutics Market Size (2018-2029)
1.6.4 Latin America Crohn’s Disease Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Crohn’s Disease Therapeutics Market Size (2018-2029)
2 Crohn’s Disease Therapeutics Market by Type
2.1 Introduction
2.1.1 Non-Surgical
2.1.2 Surgical
2.2 Global Crohn’s Disease Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Crohn’s Disease Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Crohn’s Disease Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Crohn’s Disease Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Crohn’s Disease Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Crohn’s Disease Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Crohn’s Disease Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Crohn’s Disease Therapeutics Revenue Breakdown by Type (2018-2029)
3 Crohn’s Disease Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Ambulatory Surgical Centers
3.2 Global Crohn’s Disease Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Crohn’s Disease Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Crohn’s Disease Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Crohn’s Disease Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Crohn’s Disease Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Crohn’s Disease Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Crohn’s Disease Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Crohn’s Disease Therapeutics Revenue Breakdown by Application (2018-2029)
4 Crohn’s Disease Therapeutics Competition Analysis by Players
4.1 Global Crohn’s Disease Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Crohn’s Disease Therapeutics as of 2022)
4.3 Date of Key Players Enter into Crohn’s Disease Therapeutics Market
4.4 Global Top Players Crohn’s Disease Therapeutics Headquarters and Area Served
4.5 Key Players Crohn’s Disease Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Crohn’s Disease Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Johnson and Johnson Services Inc.
5.1.1 Johnson and Johnson Services Inc. Profile
5.1.2 Johnson and Johnson Services Inc. Main Business
5.1.3 Johnson and Johnson Services Inc. Crohn’s Disease Therapeutics Products, Services and Solutions
5.1.4 Johnson and Johnson Services Inc. Crohn’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Johnson and Johnson Services Inc. Recent Developments
5.2 Pfizer Inc.
5.2.1 Pfizer Inc. Profile
5.2.2 Pfizer Inc. Main Business
5.2.3 Pfizer Inc. Crohn’s Disease Therapeutics Products, Services and Solutions
5.2.4 Pfizer Inc. Crohn’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Inc. Recent Developments
5.3 Allergan
5.3.1 Allergan Profile
5.3.2 Allergan Main Business
5.3.3 Allergan Crohn’s Disease Therapeutics Products, Services and Solutions
5.3.4 Allergan Crohn’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 AbbVie Inc. Recent Developments
5.4 AbbVie Inc.
5.4.1 AbbVie Inc. Profile
5.4.2 AbbVie Inc. Main Business
5.4.3 AbbVie Inc. Crohn’s Disease Therapeutics Products, Services and Solutions
5.4.4 AbbVie Inc. Crohn’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 AbbVie Inc. Recent Developments
5.5 Takeda Pharmaceutical Company Limited
5.5.1 Takeda Pharmaceutical Company Limited Profile
5.5.2 Takeda Pharmaceutical Company Limited Main Business
5.5.3 Takeda Pharmaceutical Company Limited Crohn’s Disease Therapeutics Products, Services and Solutions
5.5.4 Takeda Pharmaceutical Company Limited Crohn’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Takeda Pharmaceutical Company Limited Recent Developments
5.6 Celgene Corporation
5.6.1 Celgene Corporation Profile
5.6.2 Celgene Corporation Main Business
5.6.3 Celgene Corporation Crohn’s Disease Therapeutics Products, Services and Solutions
5.6.4 Celgene Corporation Crohn’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Celgene Corporation Recent Developments
5.7 Perrigo Company PLC
5.7.1 Perrigo Company PLC Profile
5.7.2 Perrigo Company PLC Main Business
5.7.3 Perrigo Company PLC Crohn’s Disease Therapeutics Products, Services and Solutions
5.7.4 Perrigo Company PLC Crohn’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Perrigo Company PLC Recent Developments
5.8 Ferring B.V.
5.8.1 Ferring B.V. Profile
5.8.2 Ferring B.V. Main Business
5.8.3 Ferring B.V. Crohn’s Disease Therapeutics Products, Services and Solutions
5.8.4 Ferring B.V. Crohn’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Ferring B.V. Recent Developments
5.9 Salix Pharmaceuticals
5.9.1 Salix Pharmaceuticals Profile
5.9.2 Salix Pharmaceuticals Main Business
5.9.3 Salix Pharmaceuticals Crohn’s Disease Therapeutics Products, Services and Solutions
5.9.4 Salix Pharmaceuticals Crohn’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Salix Pharmaceuticals Recent Developments
5.10 Gilead Sciences Inc.
5.10.1 Gilead Sciences Inc. Profile
5.10.2 Gilead Sciences Inc. Main Business
5.10.3 Gilead Sciences Inc. Crohn’s Disease Therapeutics Products, Services and Solutions
5.10.4 Gilead Sciences Inc. Crohn’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Gilead Sciences Inc. Recent Developments
5.11 Genentech Inc.
5.11.1 Genentech Inc. Profile
5.11.2 Genentech Inc. Main Business
5.11.3 Genentech Inc. Crohn’s Disease Therapeutics Products, Services and Solutions
5.11.4 Genentech Inc. Crohn’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 Genentech Inc. Recent Developments
5.12 UCB India Private Limited.
5.12.1 UCB India Private Limited. Profile
5.12.2 UCB India Private Limited. Main Business
5.12.3 UCB India Private Limited. Crohn’s Disease Therapeutics Products, Services and Solutions
5.12.4 UCB India Private Limited. Crohn’s Disease Therapeutics Revenue (US$ Million) & (2018-2023)
5.12.5 UCB India Private Limited. Recent Developments
6 North America
6.1 North America Crohn’s Disease Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Crohn’s Disease Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Crohn’s Disease Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Crohn’s Disease Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Crohn’s Disease Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Crohn’s Disease Therapeutics Market Dynamics
11.1 Crohn’s Disease Therapeutics Industry Trends
11.2 Crohn’s Disease Therapeutics Market Drivers
11.3 Crohn’s Disease Therapeutics Market Challenges
11.4 Crohn’s Disease Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
